Why Glenmark’s Asmanex Twisthaler still matters for everyday asthma control

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 22:49. Details in the imprint.

Asmanex Twisthaler from Glenmark is one of those inhalers that almost disappears in your hand, yet quietly decides how your lungs will feel in the morning. A white, palm-sized capsule, twist to arm it, breathe in deeply - that is the entire ritual. For many asthma patients, this simplicity is exactly the point.

What Asmanex Twisthaler offers

Asmanex Twisthaler is a dry powder inhaler containing mometasone furoate, an inhaled corticosteroid used for the long-term prophylactic treatment of asthma in adults and adolescents. The device is breath-actuated, so there is no need to coordinate pressing and inhaling as with many classic metered-dose inhalers.

Glenmark markets Asmanex Twisthaler in several strengths, commonly 110 µg and 220 µg delivered doses, tailored for different asthma severities and age groups. The once- or twice-daily dosing schedule is designed to keep inflammation in the airways down steadily rather than chasing symptoms after they flare.

Handling in everyday life

In the hand, Asmanex Twisthaler feels closer to a chunky marker pen than a piece of medical equipment. You twist the base until it clicks, raise it to your mouth, and inhale strongly - a short mechanical rasp, the powder lifts, and you are done.

A built-in dose counter sits on the top like a small window, ticking down with each twist so patients can see at a glance how many doses remain. When the doses are finished, the mechanism locks and the cap cannot be removed fully, a quiet but clear signal that it is time for a replacement.

Where it shines for patients

The big promise of Asmanex Twisthaler is convenience: a single maintenance inhaler, often once daily in the evening for stable patients, instead of juggling several controllers. Because the device is breath-actuated, it can be easier for people who struggle with the timing of press-and-breathe canisters, especially older adults or teenagers.

Clinical studies with mometasone furoate have shown improvements in lung function and reductions in asthma exacerbations compared with placebo, with a safety profile in line with other inhaled steroids. Many patients report fewer night-time awakenings and less morning tightness when they take their doses consistently over weeks, not days.

Limitations and typical side effects

Like all inhaled corticosteroids, Asmanex Twisthaler does not give immediate relief of an acute asthma attack; a separate short-acting bronchodilator is still needed for sudden symptoms. Patients who expect instant opening of the airways from this device alone will be disappointed, and possibly put at risk.

Typical side effects include oral candidiasis, hoarseness, throat irritation, and cough, risks that can be reduced by rinsing the mouth after inhalation. At higher long-term doses, systemic steroid effects such as reduced bone density or growth suppression in children cannot be ruled out and must be monitored by physicians.

How it compares in a crowded field

The asthma market has shifted noticeably toward combination inhalers that pair an inhaled steroid with a long-acting bronchodilator, like fluticasone-salmeterol or budesonide-formoterol. These products can simplify therapy further by combining controller components in one puff, and many guidelines now favor them for moderate to severe asthma.

Asmanex Twisthaler, as a monoproduct steroid, therefore fits best for patients with milder disease or as a foundational building block in stepwise therapy. For payers and healthcare systems, however, a steroid-only inhaler can be a cost-conscious option when more complex combinations are not necessary or affordable.

Market, price, and availability

Glenmark provides Asmanex Twisthaler mainly to markets where it has strong respiratory and generics franchises, including India and selected international territories; in some regions other companies hold the brand rights. As a prescribed medication, final prices vary sharply by country, reimbursement status, and contracted pharmacy discounts.

In its home market of India, Glenmark has been expanding its respiratory portfolio as part of its “Glenmark 3.0” strategy, focusing on complex inhalation products and specialty therapies rather than pure commodity generics. Asmanex Twisthaler fits neatly into this push toward higher-value respiratory offerings for chronic diseases.

Company context and stock reference

Respiratory medicines, alongside dermatology and oncology, are key therapeutic pillars for Glenmark Pharmaceuticals, which is increasingly leaning on specialty and branded generics to support margins. Shares of Glenmark Pharmaceuticals (INE935A01035) traded on 2026-06-18 on the NSE in India around ?2,156 per share.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.